News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe


Patients Wade into EU Pricing Debate

Patient associations have waded vigorously into the intense debate now starting on how to update the 20-year-old European Union regimen for pricing and reimbursement. Their intervention brings an additional dimension to the concerns voiced so far about this review of fundamental EU rules — notably pharmaceutical companies' fears that the outcome may mean tougher assessments of relative efficacy, or warnings from national health ministries that demands for faster decision-making are unrealistic. "The revision of the rules is important for patients," too, says the European Patients Forum (EPF) — which represents more than 50 diverse patient organisations, ranging from giants like Alzheimer Europe to smaller outfits such as the Malta Health Network or the Estonian Chamber of Disabled People.

EPF has already drafted a position on the proposals that emerged from the European Commission last February, and gave its members until the end of July to comment. It wants to be sure it is equipped to maximise patient input into the formal debates on the new legislation that will start in the European Parliament and the EU's Council of Ministers after the summer break. So EPF is liaising with the Commission, key members of the European Parliament and what it loosely refers to as "other stakeholders" to prepare the ground for influencing the debates as proposals are turned into laws.

The starting point of the draft EPF position is that "there are currently wide and unjustifiable delays in access to new medicines across the EU." One of its targets is the inconsistency displayed by national drug pricing and reimbursement regimes in Europe, which it blames for leading to inequalities in access to high-quality medical care

Read more at http://PharmTech.com/PricingDebate

EC Offers Aid to Former AstraZeneca Workers


Antenna Audio, Inc./Getty Images
The European Commission is looking to provide Sweden with €4.3 million to help 700 workers affected by AstraZeneca job cuts to find new work. The proposal is currently awaiting approval from the European parliament and the EU's Council of Ministers.

AstraZeneca announced plans earlier this year to axe approximately 7300 jobs worldwide. Almost 1000 of the job cuts will be in Sweden stemming from the closure of R&D sites in Lund and Umeĺ, and the limiting of operations in Mölndal and Södertälje. Of the 987 redundant workers, 700 who face the most difficulties in finding new jobs are being targeted for support. The estimated total cost of the support package is around €6.6 million, €4.3 million of which will come from the European Globalisation Adjustment Fund (EGF), which was established in 2006 with the aim of helping workers who have lost their jobs because of changing global trade patterns or the global financial crisis.

In a statement, the EU Commissioner for Employment, Social Affairs and Inclusion, László Andor, said, "The pharmaceutical industry is currently undergoing significant changes in order to retain its competitiveness in a tough environment, and it is therefore increasingly seeking synergies to hold down the rising costs of R&D activities."

Since the start of its operations in 2007, the EGF has received 101 applications, with more than €430 million being requested to help around 90481 workers. Applications are being received for a growing number of sectors and an increasing number of EU member states.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here